戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 scle mechanism independent of an endothelial bradykinin receptor.
2 allikrein enzymes that activate it, and both bradykinin receptors.
3 res kallikrein activity but does not involve bradykinin receptors.
4 um channels in sensory neurons by activating bradykinin receptors.
5 activation but attenuating those mediated by bradykinin receptors.
6  to produce IL-12 through activation of B(2) bradykinin receptors.
7 e mediated by bradykinin acting on B1 and B2 bradykinin receptors.
8 for the interaction of the kinins with human bradykinin receptor 1 (B1) using site-directed mutagenes
9 I/D) angiotensin-converting enzyme (ACE) and bradykinin receptor (+9/-9) genotypes were identified in
10                                       The B2 bradykinin receptor, a seven-helix transmembrane recepto
11  ASIC1a activity is independent of opioid or bradykinin receptor activation but is prevented in the p
12  P2Y(2)-Rs because it was mimicked by apical bradykinin receptor activation, and it did not result fr
13 duced VEGF secretion was dependent on the B2 bradykinin receptor, activation of protein kinase C, and
14                 Similarly, pretreatment with bradykinin receptor agonists inhibited IL-8-induced neut
15 culum; estimation of the distribution of the bradykinin receptor along the surface of a neuronal cell
16                               Absence of the bradykinin receptors also enhances the diabetes-associat
17 o promote pain through its agonist action at bradykinin receptors and suggest new avenues for therape
18 smic reticulum calcium ATPase (SERCA) pumps, bradykinin receptors, and ER] were based on 3D confocal
19                                              Bradykinin receptor antagonism did not affect the mean a
20 , neutralizing antibody to prekallikrein and bradykinin receptor antagonism.
21 kinin receptor antagonist HOE 140 and the B1 bradykinin receptor antagonist des-Arg9[Leu8]bradykinin
22 .8 microg/min) in 24 smokers pretreated with bradykinin receptor antagonist HOE 140 (100 microg/kg in
23                                       The B2 bradykinin receptor antagonist HOE 140 and the B1 bradyk
24  prevented by concomitant treatment with the bradykinin receptor antagonist icatibant.
25                       Recently, icatibant, a bradykinin receptor antagonist, has been used to success
26 tudy were to determine the doses of B9340, a bradykinin receptor antagonist, that inhibit vasodilatat
27                    In this study, a specific bradykinin-receptor antagonist, icatibant acetate (HOE 1
28                                              Bradykinin receptor antagonists may be of benefit in tre
29 disrupts signaling at P2Y receptors and that bradykinin receptors are not prelocalized to cholesterol
30 n variants located in close proximity to the bradykinin receptor B(2) gene were associated with incre
31 dels by monitoring the association of type 2 bradykinin receptor (B(2)R) and the Galpha(q)/Gbetagamma
32 etylcholine receptor (M(1)AchR) and the B(2) bradykinin receptor (B(2)R).
33                                          The bradykinin receptor B1R is overexpressed in many human c
34 efore explored the influence of lack of both bradykinin receptors (B1R and B2R) on diabetic nephropat
35                              Coexpression of bradykinin receptor B2 (BKRB2), a Galphaq/11-coupled rec
36 ghlighted previously reported genes (BDKRB2 [bradykinin receptor B2] and F5 [coagulation factor 5]) a
37                                     However, bradykinin receptors became nearly as effective as M1 re
38                                              Bradykinin receptor blockade reversed the inhibitory eff
39 regulated dynorphin A (Dyn A) interacts with bradykinin receptors (BRs) in the spinal cord to promote
40 he authors report that the stimulation of B2 bradykinin receptors by bradykinin triggers the release
41 oser to helix 7 and helix 1 as compared with bradykinin-receptor complex models.
42 rat M(1)-muscarinic receptor, and human B(1)-bradykinin receptor did not alter the properties of the
43  (STIA) model, mice that lacked HK, pKal, or bradykinin receptors displayed protective phenotypes in
44 he known effect of oncogenic Ras to increase bradykinin receptor expression and the ability of PDGF t
45 lotting showed significant elevation of B(2)-bradykinin receptor expression in all normotensive anima
46    We have cloned and sequenced the human B1 bradykinin receptor gene (BDKRB1), which contains an uni
47                 To determine the presence of bradykinin receptors in skeletal muscle, we examined in
48  Ca2+ sensor-1 were blocked, suggesting that bradykinin receptor-induced intracellular Ca2+ increases
49                             We conclude that bradykinin receptors inhibit M current of sympathetic ne
50                                          The bradykinin receptor is a G protein-coupled receptor (GPC
51                  This action of dynorphin at bradykinin receptors is distinct from the primary signal
52 es demonstrate that urothelial expression of bradykinin receptors is plastic and is altered by pathol
53 states of a single binding site, we examined bradykinin receptors on a pure skeletal muscle system, t
54 , which acts via G protein-coupled B1 and B2 bradykinin receptors on VSMCs and endothelial cells.
55                     Thus, both the B1 and B2 bradykinin receptors play an important role in reducing
56 n mediated the enhancing action of purine or bradykinin receptor stimulation on eNOS Ser-635/633 phos
57 produce IL-12 through activation of the B(2) bradykinin receptor subtype and that bradykinin-induced
58 nvestigated the localization and function of bradykinin receptor subtypes B1 and B2 in the normal and
59 , we studied the human B2 (B2R) and B1 (B1R) bradykinin receptor subtypes in HEK293 cells.
60   To assess whether this represents multiple bradykinin receptor subtypes present in skeletal muscle
61                 After activation of the B(2) bradykinin receptor, the electric field sensed by the dy
62 kinin release) or antagonists of endothelial bradykinin receptors (to prevent downstream bradykinin a
63 at have been reported to reside in caveolae, bradykinin receptor type 2 (B(2)R), which is coupled to
64 a signaling pathway initiated by the B2 type bradykinin receptor via G(q) activation, which leads to
65 on day 1 postinjury, whereas the increase in bradykinin receptors was gradual after day 3 postinjury.
66 t of the C-terminal domain of the human B(1)-bradykinin receptor with the C-terminal domains of eithe
67 is known about the cell types expressing the bradykinin receptor within the brain.